A beta 2-agonist, procaterol, inhibits basophil migration. 1995

M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
Department of Medicine and Physical Therapy, University of Tokyo School of Medicine, Japan.

Beta 2-receptor agonists have recently been reported to be effective on allergen-induced late-phase reaction (LPR) in addition to their inhibitory effect on immediate-phase reaction, although the precise mechanism is not fully understood. In this study, we tested the effect of a selective beta 2-agonist, procaterol, on human basophil migration, which may be an important characteristic of LPR. Procaterol inhibited IL-8- and C5a-induced basophil migration in a dose-dependent fashion; 10(-7) M of procaterol reduced 30% of migration induced by both factors. The action of procaterol was rapid since the inhibition of migration was detected without preincubation and was not via the toxic effect on basophils as assessed by trypan blue test. The results of this study extend the repertoire of anti-inflammatory actions of beta 2-agonists.

UI MeSH Term Description Entries
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D001491 Basophils Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. Basophil
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015936 Complement C5a The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION. C5a Complement,Complement 5a,Complement Component 5a,C5a, Complement,Complement, C5a,Component 5a, Complement
D016209 Interleukin-8 A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells. CXCL8 Chemokine,Chemokine CXCL8,Chemotactic Factor, Macrophage-Derived,Chemotactic Factor, Neutrophil, Monocyte-Derived,IL-8,Neutrophil-Activating Peptide, Lymphocyte-Derived,Neutrophil-Activating Peptide, Monocyte-Derived,AMCF-I,Alveolar Macrophage Chemotactic Factor-I,Anionic Neutrophil-Activating Peptide,Chemokines, CXCL8,Chemotactic Factor, Neutrophil,Granulocyte Chemotactic Peptide-Interleukin-8,IL8,Monocyte-Derived Neutrophil Chemotactic Factor,Neutrophil Activation Factor,Alveolar Macrophage Chemotactic Factor I,Anionic Neutrophil Activating Peptide,CXCL8 Chemokines,CXCL8, Chemokine,Chemokine, CXCL8,Chemotactic Factor, Macrophage Derived,Chemotactic Peptide-Interleukin-8, Granulocyte,Granulocyte Chemotactic Peptide Interleukin 8,Interleukin 8,Lymphocyte-Derived Neutrophil-Activating Peptide,Macrophage-Derived Chemotactic Factor,Monocyte-Derived Neutrophil-Activating Peptide,Neutrophil Activating Peptide, Lymphocyte Derived,Neutrophil Activating Peptide, Monocyte Derived,Neutrophil Chemotactic Factor,Neutrophil-Activating Peptide, Anionic,Peptide, Anionic Neutrophil-Activating
D017265 Procaterol A long-acting beta-2-adrenergic receptor agonist. (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone,CI-888,OPC-2009,Pro-Air,Procaterol Hydrochloride,Procaterol Monohydrochloride,Procaterol Monohydrochloride, (R*,R*)-(+)-Isomer,Procaterol Monohydrochloride, (R*,R*)-(+-)-Isomer,Procaterol Monohydrochloride, (R*,R*)-(-)-Isomer,Procaterol Monohydrochloride, (R*,S*)-(+)-Isomer,Procaterol Monohydrochloride, (R*,S*)-(-)-Isomer,Procaterol, (R*,R*)-(+-)-Isomer,Procaterol, (R*,S*)-(-)-Isomer,CI 888,CI888,Hydrochloride, Procaterol,Monohydrochloride, Procaterol,OPC 2009,OPC2009,Pro Air,ProAir

Related Publications

M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
December 2009, Inflammation,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
September 2007, Allergology international : official journal of the Japanese Society of Allergology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
June 1985, British journal of clinical pharmacology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
June 1985, The Journal of allergy and clinical immunology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
January 1985, British journal of pharmacology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
October 1987, Allergy,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
January 1978, Biochemical pharmacology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
April 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
M Yamaguchi, and K Hirai, and K Ohta, and K Ito, and Y Morita
August 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Copied contents to your clipboard!